Business
INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many
About this update from Invo Fertility, Inc.
[{"type":"text","content":"- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. \n- The INVOcell solution provides an advanced, effective and affordable infertility treatment to help increase access to care. \n- INVO Is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.\nSARASOTA, Fla. and ANAHEIM, Calif., Nov. 1, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture (\"IVC\") procedure it enables, today announced a successful showcasing of INVOcell at last week's 2022 Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) held on October 22-26, 2022 in Anaheim, California.\n\n \n \n \n \n \n \n\n \nCheck out this video titled \"How INVOcell Works\": https://vimeo.com/725014908.\n\"INVO's cumulative progress over the past two years, on both the commercial front as well as additional real world patient outcomes data, allowed us to further highlight our innovative INVOcell solution at last week's ASRM conference,\" commented Steve Shum, CEO of INVO Bioscience. \"It was clear at this year's annual conference that INVOcell's presence in the marketplace is growing, and our expanded commercial approach is attractive. Our business development team engaged in a number of productive discussions with interested parties at the conference revolving around our commercial efforts toward providing INVOcell to existing clinics, opening our own INVO Centers, and now selectively acquiring existing fertility practices.\"\nImportant to the recent progress, over the past year, INVO Bioscience opened, in collaboration with physician partners, three North American-based INVO Centers focused on offering IVC as an advanced and affordable alternative to IVF, utilizing INVOcell. The Company has also announced plans to open centers in Kansas City, Tampa Bay, and the San Francisco Bay Area with the goal of further expanding to o...